FibroBiologics’ Matrix-Free Thymus Organoids Generate Diverse T Cells, Slow Melanoma Growth
FibroBiologics’ thymic organoid platform produced multiple T cell lineages—αβ, γδ, NKT, and FoxP3+ cells—in immunodeficient mice, demonstrating rapid, matrix-free, cryopreservable, injectable organoids can restore thymic output. In melanoma models, antigen-specific organoid-derived T cells slowed tumor growth and activated NK cells, highlighting broad therapeutic and valuation upside.
1. Thymic Organoid Platform
FibroBiologics developed transplantable thymic micro-organoids using selectively screened fibroblasts combined with thymic stromal cells. The platform relies on a three-day, matrix-free culture process to produce cryopreservable, injectable organoids designed for clinical scalability.
2. Immune Cell Generation in Mice
In immunodeficient mouse models, transplanted organoids generated αβ, γδ, natural killer T and FoxP3+ regulatory T cells with a diverse T cell receptor repertoire. Functional assays confirmed the organoid-derived cells responded to multiple immune stimuli, indicating authentic restoration of thymic function.
3. Anti-Tumor Activity in Melanoma Model
Organoids derived from pmel-1 thymocytes produced antigen-specific T cells that slowed melanoma tumor growth and enhanced natural killer cell activation. Consistent effects across tumor sites and draining lymph nodes demonstrated a systemic anti-tumor immune response.
4. Therapeutic and Commercial Outlook
These preclinical results support applications in reversing age-related immune decline, aiding recovery after chemotherapy or radiation, and treating congenital thymic disorders. Successful translation to clinical trials could drive significant valuation appreciation for FibroBiologics.